307 related articles for article (PubMed ID: 10816544)
21. Does Bordetella pertussis vaccine offer any cross-protection against Bordetella bronchiseptica? Implications for pet owners with cystic fibrosis.
Moore JE; Rendall JC; Millar BC
J Clin Pharm Ther; 2021 Oct; 46(5):1194-1198. PubMed ID: 33470435
[TBL] [Abstract][Full Text] [Related]
22. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
Taranger J; Trollfors B; Bergfors E; Knutsson N; Lagergård T; Schneerson R; Robbins JB
Pediatrics; 2001 Dec; 108(6):E115. PubMed ID: 11731642
[TBL] [Abstract][Full Text] [Related]
23. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model.
Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M
Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
Boucher P; Sato H; Sato Y; Locht C
Infect Immun; 1994 Feb; 62(2):449-56. PubMed ID: 7507893
[TBL] [Abstract][Full Text] [Related]
25. [Antigenic variability of Bordetella pertussis strains isolated in 1967-2010 in the Czech Republic--possible explanation for the rise in cases of pertussis?].
Zavadilová J; Lžičařová D; Musílek M; Křížová P; Fabiánová K
Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):130-8. PubMed ID: 26448300
[TBL] [Abstract][Full Text] [Related]
26. Population diversity among Bordetella pertussis isolates, United States, 1935-2009.
Schmidtke AJ; Boney KO; Martin SW; Skoff TH; Tondella ML; Tatti KM
Emerg Infect Dis; 2012 Aug; 18(8):1248-55. PubMed ID: 22841154
[TBL] [Abstract][Full Text] [Related]
27. Antibody Specificity Following a Recent
Raeven RHM; van der Maas L; Pennings JLA; Fuursted K; Jørgensen CS; van Riet E; Metz B; Kersten GFA; Dalby T
Front Immunol; 2019; 10():1364. PubMed ID: 31275314
[No Abstract] [Full Text] [Related]
28. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland.
Mooi FR; He Q; van Oirschot H; Mertsola J
Infect Immun; 1999 Jun; 67(6):3133-4. PubMed ID: 10338531
[TBL] [Abstract][Full Text] [Related]
29. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
30. Genetic and antigenic analysis of Bordetella pertussis isolates recovered from clinical cases in Ontario, Canada, before and after the introduction of the acellular pertussis vaccine.
Tsang RS; Sill ML; Martin IE; Jamieson F
Can J Microbiol; 2005 Oct; 51(10):887-92. PubMed ID: 16333349
[TBL] [Abstract][Full Text] [Related]
31. Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.
Rappuoli R; Pizza M; Covacci A; Bartoloni A; Nencioni L; Podda A; De Magistris MT
FEMS Microbiol Immunol; 1992 Oct; 5(4):161-70. PubMed ID: 1384602
[TBL] [Abstract][Full Text] [Related]
32. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D
Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837
[TBL] [Abstract][Full Text] [Related]
33. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada.
Tsang RS; Lau AK; Sill ML; Halperin SA; Van Caeseele P; Jamieson F; Martin IE
J Clin Microbiol; 2004 Nov; 42(11):5364-7. PubMed ID: 15528744
[TBL] [Abstract][Full Text] [Related]
35. Transfer of a pertussis toxin expression locus to isogenic bvg-positive and bvg-negative strains of Bordetella bronchiseptica using an in vivo technique.
Smith AM; Walker MJ
Microb Pathog; 1996 May; 20(5):263-73. PubMed ID: 8861392
[TBL] [Abstract][Full Text] [Related]
36. Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants?
He Q; Mäkinen J; Berbers G; Mooi FR; Viljanen MK; Arvilommi H; Mertsola J
J Infect Dis; 2003 Apr; 187(8):1200-5. PubMed ID: 12695998
[TBL] [Abstract][Full Text] [Related]
37. Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection.
Suzuki K; Shinzawa N; Ishigaki K; Nakamura K; Abe H; Fukui-Miyazaki A; Ikuta K; Horiguchi Y
Microbiol Immunol; 2017 Sep; 61(9):371-379. PubMed ID: 28752940
[TBL] [Abstract][Full Text] [Related]
38. Localization of the promoter for the ptl genes of Bordetella pertussis, which encode proteins essential for secretion of pertussis toxin.
Kotob SI; Hausman SZ; Burns DL
Infect Immun; 1995 Aug; 63(8):3227-30. PubMed ID: 7622254
[TBL] [Abstract][Full Text] [Related]
39. Cloning and immunologic characterization of a truncated Bordetella bronchiseptica filamentous hemagglutinin fusion protein.
Keil DJ; Burns EH; Kisker WR; Bemis D; Fenwick B
Vaccine; 1999 Dec; 18(9-10):860-7. PubMed ID: 10580199
[TBL] [Abstract][Full Text] [Related]
40. Stable expression of pertussis toxin in Bordetella bronchiseptica under the control of a tightly regulated promoter.
Suarez A; Staendner LH; Rohde M; Piatti G; Timmis KN; Guzmán CA
Appl Environ Microbiol; 1997 Jan; 63(1):122-7. PubMed ID: 8979346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
